Masataka Yanagawa retweetledi

DREADDs in humans--update:
3 clinical trials using hM4Di in humans registered in China. 2 for epilepsy and 1 for Parkinson's Disease.
In our original paper we stated:
"...We suggest that at least one of these designer receptors, hM4D, will prove useful for neuronal silencing in vitro and in vivo.."
It seems we were correct.

GIF
English



















